Allurion Technologies shares catapulted Friday after the medtech company said it plans to test its weight-loss technology in combination with an obesity drug. Please watch the video at Investors ...

At 48 weeks, Allurion Balloon subjects had a greater than 50% responder rate and substantially greater weight loss than Control subjects Low rate of serious adverse events supports favorable ...

If you can’t beat them then join them. In a bid to combat weakening financial performance, Allurion has revealed plans to initiate a clinical study evaluating its weight loss programme in ...